$AMGN Headlines Amgen ends trials of stomach-c
Post# of 72749
Posted On: 12/07/2014 1:02:43 PM
$AMGN Headlines
Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt
Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting 11:00 a.m. Dec. 6, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:22 p.m. Dec. 5, 2014 - TheStreet.com
Bayer Files Hemophilia A Drug Marketing Application in EU - Analyst Blog 10:20 a.m. Dec. 5, 2014 - Zacks.com
Amgen Inc. (AMGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 5, 2014 - Zacks.com
Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning - Analyst Blog 6:45 p.m. Dec. 4, 2014 - Zacks.com
ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog 6:30 p.m. Dec. 4, 2014 - Zacks.com
Hot Drugmakers Build More Labs, Grab Space In Boston 3:47 p.m. Dec. 4, 2014 - Investors Business Daily
Gilead Sciences: An Alpha Stock Through The Good And Bad Times 3:14 p.m. Dec. 4, 2014 - Seeking Alpha
Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog 3:10 p.m. Dec. 4, 2014 - Zacks.com
Cancer’s Super-Survivors 1:46 p.m. Dec. 4, 2014 - The Wall Street Journal Interactive Edition
Insider Trading Alert - CVT, ARAY And AMGN Traded By Insiders 10:15 a.m. Dec. 4, 2014 - TheStreet.com
Regeneron at 52-Week High on Eylea Priority Review Status - Analyst Blog 9:15 a.m. Dec. 4, 2014 - Zacks.com
Oncolytics Files for Orphan Drug Designation for Reolysin - Analyst Blog 4:30 p.m. Dec. 3, 2014 - Zacks.com
Biogen Up on Encouraging Interim Data on Alzheimer's Drug - Analyst Blog 2:33 p.m. Dec. 3, 2014 - Zacks.com
Amgen Wins U.S. Approval for Immunotherapy Against Leukemia 1:31 p.m. Dec. 3, 2014 - TheStreet.com
FDA clears Amgen blood cancer immunotherapy 1:25 p.m. Dec. 3, 2014 - Seeking Alpha
Pharmacyclics, J&J Seek Imbruvica Label Expansion in EU - Analyst Blog 6:05 p.m. Dec. 2, 2014 - Zacks.com
Amgen (AMGN) Reaches New Lifetime High Today 9:45 a.m. Dec. 2, 2014 - TheStreet.com
Meet 5 Top Drug Stocks That Are Bolting Past Market 7:02 a.m. Dec. 2, 2014 - Investors Business Daily
'Fast Money' Recap: Energy Companies Ebb and Flow With Oil Prices 5:00 a.m. Dec. 2, 2014 - TheStreet.com
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 1:00 p.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 11:00 a.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition 7:00 p.m. Dec. 3, 2014 - PR Newswire - PRF
Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources 4:30 p.m. Dec. 3, 2014 - PR Newswire - PRF
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 3:48 p.m. Dec. 3, 2014 - PR Newswire - PRF
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment 9:06 a.m. Dec. 2, 2014 - Marketwired
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment 4:06 p.m. Nov. 27, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 25, 2014 - PR Newswire - PRF
Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer 9:15 a.m. Nov. 24, 2014 - PR Newswire - PRF
Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel 8:01 a.m. Nov. 19, 2014 - BusinessWire - BZX
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 4:00 p.m. Nov. 18, 2014 - PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza 4:05 p.m. Nov. 17, 2014 - GlobeNewswire
Amgen To Present At The Jefferies Global Healthcare Conference 4:15 p.m. Nov. 14, 2014 - PR Newswire - PRF
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver 9:31 a.m. Nov. 13, 2014 - PR Newswire - PRF
Biothera Names Carey Anderson VP of Regulatory Affairs 9:30 a.m. Nov. 13, 2014 - BusinessWire - BZX
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions 4:35 p.m. Nov. 12, 2014 - PR Newswire - PRF
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab 4:01 p.m. Nov. 12, 2014 - PR Newswire - PRF
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide 9:00 a.m. Nov. 12, 2014 - PR Newswire - PRF
Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt
Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting 11:00 a.m. Dec. 6, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:22 p.m. Dec. 5, 2014 - TheStreet.com
Bayer Files Hemophilia A Drug Marketing Application in EU - Analyst Blog 10:20 a.m. Dec. 5, 2014 - Zacks.com
Amgen Inc. (AMGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 5, 2014 - Zacks.com
Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning - Analyst Blog 6:45 p.m. Dec. 4, 2014 - Zacks.com
ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog 6:30 p.m. Dec. 4, 2014 - Zacks.com
Hot Drugmakers Build More Labs, Grab Space In Boston 3:47 p.m. Dec. 4, 2014 - Investors Business Daily
Gilead Sciences: An Alpha Stock Through The Good And Bad Times 3:14 p.m. Dec. 4, 2014 - Seeking Alpha
Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog 3:10 p.m. Dec. 4, 2014 - Zacks.com
Cancer’s Super-Survivors 1:46 p.m. Dec. 4, 2014 - The Wall Street Journal Interactive Edition
Insider Trading Alert - CVT, ARAY And AMGN Traded By Insiders 10:15 a.m. Dec. 4, 2014 - TheStreet.com
Regeneron at 52-Week High on Eylea Priority Review Status - Analyst Blog 9:15 a.m. Dec. 4, 2014 - Zacks.com
Oncolytics Files for Orphan Drug Designation for Reolysin - Analyst Blog 4:30 p.m. Dec. 3, 2014 - Zacks.com
Biogen Up on Encouraging Interim Data on Alzheimer's Drug - Analyst Blog 2:33 p.m. Dec. 3, 2014 - Zacks.com
Amgen Wins U.S. Approval for Immunotherapy Against Leukemia 1:31 p.m. Dec. 3, 2014 - TheStreet.com
FDA clears Amgen blood cancer immunotherapy 1:25 p.m. Dec. 3, 2014 - Seeking Alpha
Pharmacyclics, J&J Seek Imbruvica Label Expansion in EU - Analyst Blog 6:05 p.m. Dec. 2, 2014 - Zacks.com
Amgen (AMGN) Reaches New Lifetime High Today 9:45 a.m. Dec. 2, 2014 - TheStreet.com
Meet 5 Top Drug Stocks That Are Bolting Past Market 7:02 a.m. Dec. 2, 2014 - Investors Business Daily
'Fast Money' Recap: Energy Companies Ebb and Flow With Oil Prices 5:00 a.m. Dec. 2, 2014 - TheStreet.com
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 1:00 p.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 11:00 a.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition 7:00 p.m. Dec. 3, 2014 - PR Newswire - PRF
Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources 4:30 p.m. Dec. 3, 2014 - PR Newswire - PRF
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 3:48 p.m. Dec. 3, 2014 - PR Newswire - PRF
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment 9:06 a.m. Dec. 2, 2014 - Marketwired
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment 4:06 p.m. Nov. 27, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 25, 2014 - PR Newswire - PRF
Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer 9:15 a.m. Nov. 24, 2014 - PR Newswire - PRF
Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel 8:01 a.m. Nov. 19, 2014 - BusinessWire - BZX
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 4:00 p.m. Nov. 18, 2014 - PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza 4:05 p.m. Nov. 17, 2014 - GlobeNewswire
Amgen To Present At The Jefferies Global Healthcare Conference 4:15 p.m. Nov. 14, 2014 - PR Newswire - PRF
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver 9:31 a.m. Nov. 13, 2014 - PR Newswire - PRF
Biothera Names Carey Anderson VP of Regulatory Affairs 9:30 a.m. Nov. 13, 2014 - BusinessWire - BZX
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions 4:35 p.m. Nov. 12, 2014 - PR Newswire - PRF
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab 4:01 p.m. Nov. 12, 2014 - PR Newswire - PRF
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide 9:00 a.m. Nov. 12, 2014 - PR Newswire - PRF
(0)
(0)